



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: G. NOWAK et al.

Examiner: SANDRA E. SAUCIER

Serial No.: 09/890,654

Group Art Unit: 1651

Filed: November 5, 2001

Title: METHOD FOR DETERMINING THE CONCENTRATION OF THROMBIN INHIBITORS

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In response to the office action dated March 11, 2003, applicants elect, with traverse, Group II (claims 9-12) drawn to a first composition and a kit.

It is respectfully submitted that the subject matter of the claims does have unity of invention. For example, Group II is drawn to a kit that contains, e.g., the components for carrying out the method of Group I. Further, the claims of Groups I and II are disclosed as having common utilities (e.g., for determining the concentration of thrombin inhibitors in a body liquid). Nothing more is required. See *In re Harnisch*, 206 USPQ 300 (CCPA 1980). Therefore, at the very least, Groups I and II should be examined together. Furthermore, the Examiner has not established that a search of Groups I-III would present a serious burden. Absent a serious burden of examination, restriction is not proper. See M.P.E.P. §803. Thus, the requirement should be withdrawn.


#8
4/15/03
J. Meuser
RECEIVED
APR 10 2003
TECH CENTER 1600/2000

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)



Nicole E. Kinsey, Reg. No. 50,723
Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: April 9, 2003